Northwest Biotherapeutics (NWBO) Accumulated Expenses (2010 - 2017)

Northwest Biotherapeutics' Accumulated Expenses history runs 8 years deep, the most recent figure standing at $933000.0 for Q1 2017.

• On a quarterly basis, Accumulated Expenses fell 21.53% year-over-year to $933000.0 in Q1 2017; TTM through Mar 2017 was $933000.0, a 21.53% decrease from a year earlier, with the FY2016 full-year figure at $901000.0, down 31.17% from the prior year.
• Accumulated Expenses rose to $933000.0 in Q1 2017 per NWBO's latest filing, from $901000.0 in the prior quarter.
• Across five years, Accumulated Expenses topped out at $1.3 million in Q2 2016 and bottomed at $655000.0 in Q2 2014.
• The 5-year median for Accumulated Expenses is $1.1 million (2013), against an average of $1.0 million.
• Across the five-year window, Accumulated Expenses plunged 85.71% in 2013 and surged 81.37% in 2015, its largest moves.
• Year by year, Accumulated Expenses stood at $842000.0 in 2013, then jumped by 43.82% to $1.2 million in 2014, then grew by 8.09% to $1.3 million in 2015, then sank by 31.17% to $901000.0 in 2016, then rose by 3.55% to $933000.0 in 2017.
• Per Business Quant, the three latest NWBO Accumulated Expenses figures stand at $933000.0 (Q1 2017), $901000.0 (Q4 2016), and $1.3 million (Q3 2016).